IDEXX Laboratories, Inc. (IDXX) Analyst Ratings & Price Targets

IDEXX Laboratories, Inc.

IDXX · Nasdaq

Analyst Consensus

Buy

13 analysts

$510

Current

—

Low

$705

Average

—

High

Average target implies +38.35% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Buy across 13 analysts, with a mean price target of $745. The low and high targets were not provided, so the target spread cannot be quantified and the most- and least-bullish analysts cannot be identified. The mean target is above the latest $588.09 close, but the evidence does not establish how widely individual targets cluster around it. No named analyst rating changes, target revisions, or other revisions were supplied for the past week, so their direction cannot be determined. The substantive disagreement visible in the available evidence is between the stronger earnings, margins, diagnostics demand, and raised EPS outlook on one side, and the narrowed full-year revenue outlook on the other.

Rating Actions

1 firm captured

Firm	Analyst	Rating	Price Target	Upside	Date	Source
Weiss Ratings	—	hold (c+) upgraded	—	—	Jul 29, 2026	Open the report this row came from

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BARCLAYS CAPITA

CLEVELAND RESEA

CO FORECST

EXANE BNP PARIB

GOLDMAN SACHS

JP MORGAN SECUR

MORGAN STANLEY

PIPER SANDLER

ROTHSCHILD REDB

STIFEL NICOLAUS

WILLIAM BLAIR

ZACKS RESEARCH

Symbol: IDXX
Type: Stock
Sector: Health Care
Industry: In Vitro & In Vivo Diagnostic Substances
Exchange: Nasdaq

IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions-to advance medical care, improve efficiency, and build thriving practices. Our innovations also help measure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500 Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: www.idexx.com.

Key Issues

Bullish view

Management raised its full-year EPS outlook after a second-quarter earnings beat, suggesting operating performance is running ahead of expectations.

Bearish view

The company narrowed its full-year revenue outlook even while lifting EPS guidance, indicating that the earnings improvement may rely more on margins than on a broader revenue outlook.

Analyst Consensus

See all

Buy

13 analysts

$510

Current

—

Low

$705

Average

—

High

Average target implies +38.35% versus the current price.

Earnings History

BeatMissNo estimate

IDEXX Laboratories, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers